Deep Lens raises $3.2m to Market its Flagship Technology- VIPER

In order to market its flagship technology VIPER, the US-based digital pathology startup, Deep Lens, Inc., has raised $3.2m in its seed financing. The round was led by Sierra Ventures, with participation from Rev1 Ventures and Tamarind Hill Fund.

Deep Lens raises .2m to Market its Flagship Technology, VIPER

As the part of the financing, Mark Shary, managing member of Tamarind Hill, and Dr. Jeff Elton, CEO of Concerto Health AI, will join the company as the board of directors.

Founded by Simon Arkell, Dave Billiter and T.J. Bowen in Dave Billiter, Deep Lens is a digital pathology startup combining artificial intelligence (AI) and advanced, cloud-based, pathology workflows to improve efficiency and enable patient access to cancer clinical trials.

With the feedback received over the last 10 years, the company has developed a flagship technology called VIPER (Virtual Imaging for Pathology Education and Research), a full stack solution consisting of an artificially intelligent (AI) image detection suite, feedback tools, cloud storage, and APIs for integration with hardware and applications — all designed to facilitate peer-to-peer collaboration and clinical research. It’s now available as a public beta. Soon, the technology will be made available free of charge to all pathologists with alongside Deep Lens.

Also, the company plans to use the newly raised funds for technology development and deployment. According to its co-founder CEO Dave Billiter, the money will go toward sales and marketing efforts as well as the expansion of its flagship technology, VIPER – Virtual Imaging for Pathology Education and Research.

“Our ambitious mission to support and empower pathologists around the world will require expert help on two major fronts,” said Dave Billiter, co-founder and CEO of Deep Lens. “We are engaging with pathologists and hospitals so we can evolve our offering and expand the communal reservoir of knowledge. We are also working with biopharma to support the next wave of cancer drug development and clinical trials. To execute on our vision, Deep Lens is building an innovative, passionate team and relationships with a diverse group of outside advisors.”